期刊
BRAIN RESEARCH BULLETIN
卷 126, 期 -, 页码 170-177出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.brainresbull.2016.04.009
关键词
Alzheimer's disease; Amyloid beta-protein; BACE1; beta-Secretase; Oligomer; Trafficking
资金
- JSPS, Japan [22590951]
- Intramural Research Grant for Neurological and Psychiatric Disorders of the National Center of Neurology and Psychiatry [27-9]
- Grants-in-Aid for Scientific Research [16K09688, 25461300, 22590951] Funding Source: KAKEN
beta-Secretase, widely known as beta-site APP cleaving enzyme 1 (BACE1), is a membrane-associated protease that cleaves amyloid precursor protein (APP) to generate amyloid beta-protein (A beta). As this cleavage is a pathologically relevant event in Alzheimer's disease, BACE1 is considered a viable therapeutic target. BACE1 can be regulated at the transcriptional, post-transcriptional, translational, and post-translational levels. Elucidation of the regulatory pathways of BACE1 is critical, not only for understanding the pathological mechanisms of AD but also developing effective therapeutic strategies to inhibit activity of the protease. This mini-review focuses on the post-translational regulation of BACE1, as modulation at this level is closely associated with both physiological and pathological conditions. Current knowledge on the mechanisms underlying such BACE1 regulation and their implications for therapy are discussed. (C) 2016 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据